Back to Search
Start Over
Borneol promotes berberine-induced cardioprotection in a rat model of myocardial ischemia/reperfusion injury via inhibiting P-glycoprotein expression.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2024 Nov 15; Vol. 983, pp. 177009. Date of Electronic Publication: 2024 Sep 19. - Publication Year :
- 2024
-
Abstract
- Berberine is reported to protect the heart against ischemia/reperfusion (I/R) injury, although efficacy is limited by low bioavailability. This study aims to determine whether borneol, a classic guiding drug, can enhance the cardioprotection induced by berberine and to clarify the underlying mechanisms involving P-glycoprotein (P-gp) in the heart. Adult male Sprague Dawley rats were gavaged with berberine (200 mg/kg) with or without borneol (100 mg/kg) for 7 consecutive days. A rat model of myocardial I/R injury was established by 30 min left coronary artery occlusion followed with 120 min reperfusion. The arrhythmia score, cardiac enzyme content, and myocardial infarct size were determined following reperfusion. Heart tissues were collected for Western blot and immunofluorescence analyses to measure the protein expression levels of Bcl-2, Bax, and P-gp. The results showed that administration of berberine protected the heart against I/R injury, as demonstrated by lower arrhythmia scores, serum cTnI contents, myocardial infarct size, and cardiomyocytes apoptosis. Moreover, borneol substantially enhanced the cardioprotective effects of berberine. Western blot and immunofluorescence analyses showed that both berberine and I/R injury did not alter P-gp expression in heart. In contrast, borneol combined with berberine significantly reduced P-gp levels by 43.4% (P = 0.0240). Interestingly, treatment with borneol alone decreased P-gp levels, but did not protect against myocardial I/R injury. These findings suggest that borneol, as an adjuvant drug, improved the cardioprotective effects of berberine by inhibiting P-gp expression in heart. Borneol combined with berberine administration provides a new strategy to protect the heart against I/R injury.<br />Competing Interests: Declaration of competing interest The authors have declared no conflict of interest.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Male
Rats
bcl-2-Associated X Protein metabolism
Drug Synergism
Myocardial Infarction pathology
Myocardial Infarction metabolism
Myocardial Infarction drug therapy
Myocardial Infarction prevention & control
Myocardium pathology
Myocardium metabolism
Myocytes, Cardiac drug effects
Myocytes, Cardiac metabolism
Myocytes, Cardiac pathology
Proto-Oncogene Proteins c-bcl-2 metabolism
Rats, Sprague-Dawley
Apoptosis drug effects
ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism
Berberine pharmacology
Berberine therapeutic use
Camphanes pharmacology
Cardiotonic Agents pharmacology
Cardiotonic Agents therapeutic use
Disease Models, Animal
Myocardial Reperfusion Injury metabolism
Myocardial Reperfusion Injury drug therapy
Myocardial Reperfusion Injury prevention & control
Myocardial Reperfusion Injury pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 983
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 39306269
- Full Text :
- https://doi.org/10.1016/j.ejphar.2024.177009